STRO-002-GM2: A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (clinicaltrials.gov) - Aug 23, 2025 - P1 | N=58 | Terminated | Sponsor: Sutro Biopharma, Inc. | Trial completion date: Jan 2026 ➔ Jun 2025 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2025 ➔ Jun 2025; Terminated Early
Platinum resistant • Trial completion date • Trial primary completion date • Trial termination • Epithelial Ovarian Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor
|